Public Testimonies at FDA-SSRI-Suicidality Hearings, Dec. 13, 2006
Only if one assumes that the FDA sees the drug industry as its client can some sense be made of December 13th meeting of the FDA’s Psychopharmacologic Drugs Advisory Committee in Silver Springs, Maryland.